| Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC G Recondo, M Bahcall, LF Spurr, J Che, B Ricciuti, GC Leonardi, YC Lo, ... Clinical Cancer Research 26 (11), 2615-2625, 2020 | 153 | 2020 |
| Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer B Ricciuti, S Kravets, SE Dahlberg, R Umeton, A Albayrak, SJ Subegdjo, ... Journal for ImmunoTherapy of Cancer 7 (1), 87, 2019 | 80 | 2019 |
| Characteristics of mismatch repair deficiency in sarcomas LA Doyle, JA Nowak, MJ Nathenson, K Thornton, AJ Wagner, JM Johnson, ... Modern Pathology 32 (7), 977-987, 2019 | 65 | 2019 |
| PGMD: a comprehensive manually curated pharmacogenomic database A Kaplun, JD Hogan, F Schacherer, AP Peter, S Krishna, BR Braun, ... The pharmacogenomics journal 16 (2), 124-128, 2016 | 21 | 2016 |
| MatchMiner: An open source computational platform for real-time matching of cancer patients to precision medicine clinical trials using genomic and clinical criteria J Lindsay, CDV Fitz, Z Zwiesler, P Kumari, B Van Der Veen, T Monrose, ... bioRxiv, 199489, 2017 | 20 | 2017 |
| Somatic mutations in CDH1 and CTNNB1 in primary carcinomas at 13 anatomic sites EL Busch, JL Hornick, R Umeton, A Albayrak, NI Lindeman, ... Oncotarget 8 (49), 85680, 2017 | 19 | 2017 |
| Engaging Patients in Precision Oncology: Development and Usability of a Web-Based Patient-Facing Genomic Sequencing Report IB Solomon, S McGraw, J Shen, A Albayrak, G Alterovitz, M Davies, ... JCO Precision Oncology 4, 307-318, 2020 | 15 | 2020 |
| Clinical Pan-Cancer Assessment of Mismatch Repair Deficiency Using Tumor-Only, Targeted Next-Generation Sequencing A Albayrak, AC Garrido-Castro, M Giannakis, R Umeton, MD Manam, ... JCO Precision Oncology 4, 1084-1097, 2020 | 13 | 2020 |
| COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients M Stewart, C Rodriguez-Watson, A Albayrak, J Asubonteng, A Belli, ... Plos one 16 (3), e0248128, 2021 | 9 | 2021 |
| Identification of multisite real-world patient cohorts to enable immunotherapy utilization and safety assessment CDV Fitz, E Eldridge, A Antonopoulos, P Petrone, W Caldwell, E Corbett, ... Clinical Cancer Research 26 (12 Supplement 1), 28-28, 2020 | | 2020 |
| Use of Tumor-Only Next Generation Sequencing to Identify Clinicopathologic and Genomic Correlates of Tumor Mutational Burden and Immunotherapy Response in Non-Small Cell Lung … M Awad, NR Mahadevan, A Polio, EJ Aguilar, NI Vokes, B Ricciuti, ... Stock Ownership: Gatekeeper Pharmaceuticals. Research Funding: Astellas …, 2018 | | 2018 |
| Assessing patient trial readiness for precision cancer medicine clinical trials through computational trial matching and rule-based logic applied to genomic and clinical data CDV Fitz, K Do, J Lindsay, S Hector-Barry, Z Zwiesler, P Kumari, T Mazor, ... Cancer Research 78 (13 Supplement), 2288-2288, 2018 | | 2018 |
| Development of HOPE-Genomics: An IT platform for patient-directed cancer genome sequencing education and return of results. I Solomon, J Shen, A Albayrak, G Alterovitz, E Cerami, C Del Vecchio Fitz, ... Journal of Clinical Oncology 36 (15_suppl), 1532-1532, 2018 | | 2018 |
| Mismatch Repair Deficiency in Sarcomas is Extremely Rare LA Doyle, JA Nowak, MJ Nathenson, J Johnson, A Albrayak, S George, ... MODERN PATHOLOGY 31, 23-23, 2018 | | 2018 |
